0001127602-23-001498.txt : 20230117
0001127602-23-001498.hdr.sgml : 20230117
20230117193918
ACCESSION NUMBER: 0001127602-23-001498
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220425
FILED AS OF DATE: 20230117
DATE AS OF CHANGE: 20230117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lewis Karen
CENTRAL INDEX KEY: 0001814304
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 23532618
MAIL ADDRESS:
STREET 1: APELLIS PHARMACEUTICALS, INC.
STREET 2: 100 5TH AVENUE, 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-04-25
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001814304
Lewis Karen
C/O APELLIS PHARMACEUTICALS, INC.
WALTHAM
MA
02451
1
Chief People Officer
Common Stock
2022-04-25
4
J
0
1250
0
D
22224
D
Common Stock
2023-01-12
4
A
0
19634
0
A
42075
D
Stock Option (Right to Buy)
44.90
2022-04-25
4
J
0
7500
0
D
2031-01-27
Common Stock
7500
0
D
Stock Option (Right to Buy)
52.66
2023-01-12
4
A
0
30845
52.66
A
2033-01-11
Common Stock
30845
30845
D
This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
This represents a Restricted Stock Unit award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
This includes 125 shares from the 4/29/22 ESPP Purchase and 92 shares from the 10/31/22 ESPP Purchase.
This represents the cancellation of a performance stock option granted on 01/28/2021. The performance metrics were not met.
This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.
/s/ David Watson, attorney-in-fact for Karen Lewis
2023-01-17